Effect of Cabazitaxel on the QTc Interval in Cancer Patients
NCT01087021
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
45
Enrollment
INDUSTRY
Sponsor class
Conditions
Neoplasms, Malignant
Interventions
DRUG:
Cabazitaxel (XRP6258)
Sponsor
Sanofi